Karuna Therapeutics Q4 EPS $(3.01) Misses $(2.65) Estimate
Portfolio Pulse from Benzinga Newsdesk
Karuna Therapeutics reported Q4 earnings with a loss of $(3.01) per share, missing the consensus estimate of $(2.65) by 13.58%. This represents a 35.59% increase in losses compared to the same period last year.
February 22, 2024 | 11:33 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Karuna Therapeutics reported a larger than expected quarterly loss of $(3.01) per share, missing the consensus estimate of $(2.65). This represents a significant increase in losses from the previous year.
The reported earnings miss and the significant increase in losses year-over-year are likely to negatively impact investor sentiment towards Karuna Therapeutics in the short term. Missed earnings estimates can often lead to a decrease in stock price as they may reflect underlying issues in the company's operations or market conditions.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100